Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared on LinkedIn about a recent article by Raffaele Merola et al, published in Journal of Intensive Medicine:
” ‘Cytokine storm’ is not just inflammation, it is organ failure in motion.
A new review reframes ARDS beyond lung mechanics:
- ARDS is not only a respiratory disease
- It is a systemic immune catastrophe
What really happens in ARDS?
- Dysregulated immune activation leading to excess cytokine release
- Breakdown of the alveolar – capillary barrier
- Spillover into systemic circulation
The lung becomes the source and amplifier of systemic inflammation
Why patients die is NOT hypoxemia alone
The real driver:
Multiorgan dysfunction syndrome (MODS)
Cytokines don’t stay in the lungs:
- Brain leads to BBB disruption and neuroinflammation
- Heart leads to decreased contractility and arrhythmias
- Bone marrow leads to cytopenias
- Kidney leads to AKI, microvascular ischemia
- Liver leads to coagulopathy, DIC
ARDS becomes a whole-body disease
Not all ARDS is the same
Two key phenotypes:
Hyperinflammatory
- High IL-6, IL-8, TNF
- More shock, higher mortality
- Worse ventilator outcomes
Hypoinflammatory
- Lower cytokines
- Better outcomes
Same syndrome. Different biology. Different response to therapy.
Therapy: still behind the biology
- Lung – protective ventilation leads to cornerstone
- Corticosteroids leads to evidence-supported
- Cytokine removal, biologics, MSCs leads to promising but inconsistent
The problem: we treat ARDS as one diseas
The future is precision critical care
We should move:
From:
- ‘All ARDS patients get the same protocol’
To:
- Biomarker-guided therapy
- Subphenotype – driven interventions
- Timing-based immunomodulation
Clinical takeaway
If we don’t identify who is in a cytokine storm, we will continue to dilute effective therapies in heterogeneous populations.
ARDS is not failing because treatments don’t work.
It’s failing because we treat the wrong patients, at the wrong time, with the wrong strategy.”
Title: Cytokine storm in acute respiratory distress syndrome
Authors: Raffaele Merola, Patricia R.M. Rocco, Vito Marco Ranieri, Denise Battaglini
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation
-
Jun 23, 2026, 21:19Ahmed Koriesh: Join Us for Future of Stroke Care 2026
-
Jun 23, 2026, 20:30Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV
-
Jun 23, 2026, 19:20Simos Kokkovos: 1st Ever Mobile Stroke Unit in Greece is on its way to Metropolitan Hospital